Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?

Front Immunol · 2026 · PMC12971714 · PMID 41816343

Europe PMC DOI

hedged sentence

0.1240

closest p · 2.5× alpha

0.1240

boldest claim

The sentences

did not reach statistical significancep = 0.124not close (p > 0.1)

The trend of shorter survival in patients with brain metastases did not reach statistical significance (median 4.1 months, 95%CI: 1.1–6.9 vs . 9.8 months, 95%CI: 8.0–72.4; p = 0.124), possibly due to the limited size of this subgroup.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.